Negative correlation between cerebrospinal fluid tau protein and cognitive functioning in children with acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 53, Issue 1, 2009, Pages 105-108

  Protas, Piotr T ^a   Muszynska Roslan, Katarzyna ^a   Holownia, Adam ^a   Grabowska, Aleksandra ^a   Wielgat, Przemyslaw ^a   Krawczuk Rybak, Maryna ^a   Braszko, Jan J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Cognitive functioning; Neurotoxicity; Tau protein

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TAU PROTEIN; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CEREBROSPINAL FLUID; CHILD; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; INTELLIGENCE; MAINTENANCE THERAPY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; FEMALE; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TAU PROTEINS;

EID: 66149149827     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22029     Document Type: Article

References (20)

1. Rivera GK, Pinkel D, Simone JV, et al. Treatment of acute lymphoblastic leukaemia: 30 years of experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-1295. (Pubitemid 23317327)
2. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of the Dana-Farber Consortium Protocol 9101. Blood 2001;97:1211-1216.
3. Hallbook H, Gustafsson G, Smedmyr B, et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: A comparison between a pediatric protocol and an adult protocol. Cancer 2006;107:1551-1561. (Pubitemid 44546916)
4. Kingma A, van Dommelen RI, Mooyaart EL, et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001;139:413-420. (Pubitemid 32889519)
5. Iuvone L, Mariotti P, Colosimo C, et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 2002;95:2562-2570. (Pubitemid 35424043)
6. Glover DA, Byrne J, Mills JL, et al. Impact of CNS treatment on mood in adult survivors of childhood leukemia: A report from the Children's Cancer Group. J Clin Oncol 2003;21:4395-4401. (Pubitemid 46628463)
7. Hill JM, Kornblith AB, Jones D, et al. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation. Cancer 1998;82:208-218. (Pubitemid 28070499)
8. Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev 2006;12:174-183. (Pubitemid 44646326)
9. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med 2002;2:131-150. (Pubitemid 37012501)
10. Lewczuk P, Esselmann H, Otto M, et al. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging 2004;25:273-281.
11. Paglini G, Peris L, Mascotti F, et al. Tau protein function in axonal formation. Neurochem Res 2000;25:37-42. (Pubitemid 30074273)
12. Siman R, McIntosh TK, Soltesz KM, et al. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 2004;16:311-320. (Pubitemid 38757313)
13. Van Gool SW, De Meyer G, Van de Voorde A, et al. Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia. Neurotoxicology 2004: 25:471-480. (Pubitemid 38292195)
14. Van Gool SW, Van Kerschaver E, Brock P, et al. Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies. Leukemia 2000;14:2076-2084. (Pubitemid 32042246)
15. Surtees R, Clelland J, Heales S. Cerebrospinal fluid concentrations of nitrate plus nitrite during the treatment of acute lymphoblastic leukaemia in childhood. Leuk Res 1998;22:751-754. (Pubitemid 28327482)
16. Muszynska-Roslan K, Krawczuk-Rybak M, Protas PT, et al. Level of tau protein in children treated for acute lymphoblastic leukemia. Pediatr Neurol 2006;34:367-371.
17. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-755. (Pubitemid 27490240)
18. Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev 2006;12:174-183. (Pubitemid 44646326)
19. Quinn CT, Griener JC, Bottiglieri T, et al. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. J Pediatr Hematol Oncol 2004;26:386-388. (Pubitemid 38747731)
20. Watanabe Y, Gould E, McEwen BS. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res 1992;588:341-345.